1. Inflammation/Immunology

Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173265
    CypB-IN-1 98%
    CypB-IN-1 (Compound 11) is an inhibitor of cyclophilin B (cyclophilin B) with a Kd value of 12 nM. CypB-IN-1 can be applied to the research field of metabolic dysfunction-associated steatohepatitis (MASH) and the liver fibrosis diseases resulting from it.
    CypB-IN-1
  • HY-173290
    PDE4D inhibitor 1 98%
    PDE4-IN-1 is a PDE4 inhibitor with high potency (IC50 : 8.6 nM) and selectivity over other PDE subtypes. PDE4-IN-1 inhibits the release of inflammatory cytokines and chemokines. PDE4-IN-1 greatly restores impaired cAMP-CREB signaling pathway. PDE4-IN-1 inhibits proliferation and promotes differentiation to reverse the formation of psoriasis.
    PDE4D inhibitor 1
  • HY-173293
    ASK1-IN-8 2570985-89-4 98%
    ASK1-IN-8 (Compound 35) is an orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 value of 1.8 nM. In an experimental mouse model of liver injury induced by Acetaminophen (HY-66005), ASK1-IN-8 can significantly reduce the plasma alanine transaminase (ALT) level, protecting the liver. ASK1-IN-8 can be used in research related to liver diseases.
    ASK1-IN-8
  • HY-173311
    Cbl-b-IN-28 98%
    Cbl-b-IN-28 (Compound B2) is an orally active Cbl-b inhibitor. Cbl-b-IN-28 promotes the secretion of cytokines such as IL-2 and enhances the function of immune cells by regulating the phosphorylation levels of key proteins in the T-cell receptor signaling pathway. Cbl-b-IN-28 can be used in research in the field of cancer immunology.
    Cbl-b-IN-28
  • HY-173316
    STING-IN-12 98%
    STING-IN-12 (compound Y2) is an inhibitor of STING. STING-IN-12 inhibits IFNβ gene expression (IC50=0.75μM) induced by SR717. STING-IN-12 inhibits STING pathway activation induced by the STING agonist SR717 in THP1 cells and MSA-2-induced STING pathway activation in vivo in mice.
    STING-IN-12
  • HY-173317
    STING-IN-13 98%
    STING-IN-13 is a selective STING inhibitor. STING-IN-13 can effectively inhibit downstream signaling of the STING pathway and inhibit STING-mediated inflammation. STING-IN-13 has low toxicity and can be used to study STING-related inflammatory and autoimmune diseases.
    STING-IN-13
  • HY-173321
    PAD4-IN-5 3071873-52-1 98%
    PAD4-IN-5 (Example 18) is a PAD4 inhibitor with IC50s of ≤10 nM and 101-500 nM for human PAD4 (hPAD4) under 50 µM Ca2+ and 1 mM Ca2+ conditions, respectively. PAD4-IN-5 can be used for the study of autoimmune disease, such as rheumatoid arthritis (RA).
    PAD4-IN-5
  • HY-173326
    STING-IN-14 3070953-78-2 98%
    STING-IN-14 is an inhibitor of STING (IC50: 0.6 nM). STING-IN-14 inhibits the activation of the IRF pathway in THP1-DualTM cells. STING-IN-14 can be used in autoimmune diseases research.
    STING-IN-14
  • HY-173332
    15-LOX-1 inhibitor 2 3110518-96-9 98%
    15-LOX-1 inhibitor 2 (Compound 5i) is an inhibitor of 15-lipoxygenase-1 (15-LOX-1) with an IC50 of 1.7 μM. 15-LOX-1 inhibitor 2 inhibits the activity of 15-LOX-1 enzyme, reduces the production of lipid peroxides, thereby inhibiting lipid peroxidation and protecting cells from cell death induced by RSL3 (HY-100218A). 15-LOX-1 inhibitor 2 can be used in research on cell death mechanisms, oxidative stress-related diseases and other fields.
    15-LOX-1 inhibitor 2
  • HY-173340
    LRH-1 agonist-1 98%
    LRH-1 agonist-1 (compound 74) is an agonist of LRH-1 with IC50 value of 47 μM.
    LRH-1 agonist-1
  • HY-173359
    TYK2 ligand 2 2924460-80-8 98%
    TYK2 ligand 2 is a TYK2 ligand for TYD-68 (HY-173357). TYD-68 is a highly efficient and selective CRBN-recruited TYK2 PROTAC degrader with a DC50 value of 0.42 nM. TYD-68 can be used in the study of psoriasis.
    TYK2 ligand 2
  • HY-173383
    DOPE-DOTA sodium 98%
    DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study
    DOPE-DOTA sodium
  • HY-173384
    DSPE-DOTA sodium 98%
    DSPE-DOTA sodium (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt) is a chelating lipid used as a key contrast agent in magnetic resonance imaging (MRI). DSPE-DOTA sodium can be used for imaging detection of tumors, neurological and inflammatory diseases.
    DSPE-DOTA sodium
  • HY-173399
    hSTING activator-1 98%
    hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
    hSTING activator-1
  • HY-173404
    VB-85247 98%
    VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research.
    VB-85247
  • HY-173407
    P2Y14R antagonist 4 3081687-67-1 98%
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release.
    P2Y14R antagonist 4
  • HY-173409
    AR antagonist 11 3005979-40-5 98%
    AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC50 of 0.019 μM. AR antagonist 11 is also effective against ARF877L/T878A mutant (IC50: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC50: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa).
    AR antagonist 11
  • HY-173410
    iNOs-IN-6 98%
    iNOs-IN-6 is an anti-inflammatory agent. iNOs-IN-6 inhibits NF-κB, iNOS, and MAPK expression(IC50: 0.2-0.62 μM). iNOs-IN-6 reduces IL-6, TNF-α, and IL-1β pro-inflammatory mediators levels (IC50: 0.4-0.69 μM).
    iNOs-IN-6
  • HY-173411
    DNJ-20 3081926-49-7 98%
    DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.
    DNJ-20
  • HY-173416
    Anti-inflammatory agent 100 98%
    Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory agent. Anti-inflammatory agent 100 inhibits MAPK and NF-κB signaling, and also inhibits NF-κB pathway by suppressing the phosphorylation of IκB-α and blocking nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 inhibits NO production (IC50: 0.5 μM) and TNF-α, IL-6, IL-1β secretion.
    Anti-inflammatory agent 100
Cat. No. Product Name / Synonyms Application Reactivity